| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 57.14 | 6.0% | 23.9% |
| Total Income | 57.14 | 6.0% | 23.9% |
| Expenditure | 52.10 | 8.3% | 24.3% |
| PBT | 5.09 | 13.9% | 17.6% |
| Net Profit | 3.53 | 16.9% | 18.5% |
| OPM | 8.82% | 1.93pp | 0.27pp |
| NPM | 6.18% | 1.71pp | 0.28pp |
| EPS | 0.23 | 17.9% | 15.0% |
Lifeway Foods Reports Record Q3 2025 Net Sales of $57.1 Million
04 May 2026 · 4 May, 7:21 am
Summary
Lifeway Foods announced record financial results for the third quarter ended September 30, 2025. Net sales reached $57.1 million, a 24% increase year-over-year, or approximately 29% on a comparable basis. Gross margin expanded by 300 basis points, and net income grew by 19%. The company reiterated its long-term Adjusted EBITDA target of $45–$50 million for FY 2027 and completed the first stage of its Waukesha plant expansion.
Key Highlights
- 1
Lifeway Foods achieved record net sales of $57.1 million in Q3 2025, marking a 24.0% year-over-year increase.
- 2
On a comparable basis, net sales increased by approximately 29%, driven by Lifeway Kefir.
- 3
The company experienced significant gross margin expansion of 300 basis points in Q3 2025.
- 4
Net income grew by 19% to $3.5 million, or $0.23 per basic and diluted common share, compared to $3.0 million in the prior year.
- 5
Lifeway reiterated its long-term target of $45–$50 million in Adjusted EBITDA for FY 2027.
- 6
The first stage of the Waukesha plant expansion was completed in September, increasing capacity and operational efficiency.
- 7
Lifeway continues to enter adjacent product categories, including Muscle Mates™ and Probiotic Smoothies with Collagen.
Management Comments
Julie Smolyansky
“We delivered another exceptional quarter that further solidifies Lifeway’s dominant position in the kefir category and emphasizes the growing consumer demand for our flagship Lifeway Kefir and high-protein Lifeway Farmer Cheese,” said Julie Smolyansky, President and Chief Executive Officer of Lifeway Foods. “With record net sales of $57.1 million, well ahead of the previous high set in Q2, we have once again raised the bar for our business while demonstrating the remarkable consistency of our growth trajectory. We will continue to capitalize on the powerful health and wellness consumer trends, including the surge in GLP-1 medication use and gut health awareness. We are investing heavily in our marketing efforts and our manufacturing capabilities to support our accelerating velocities and future growth. Smolyansky continued, “In addition to our topline strength, we delivered 300 basis points of gross margin expansion year-over-year in Q3. In September, we completed the first stage of our strategic Waukesha plant expansion, which has increased capacity and helped power the operational efficiency gains we are building across our business. This expansion will enable us to continue driving profitable growth for the foreseeable future as we position ourselves to meet the surging demand in our space.” “Our momentum is accelerating,” Smolyansky concluded. “We are stacking record quarters while delivering expanding margins and on-trend innovation. We have the right team in place, are executing at the highest level, and I am confident in our ability to sustain these outstanding results.”
Informational and educational content only. Not investment advice.